Barinthus Biotherapeutics plc (BRNS)

Barinthus Biotherapeutics Statistics

Total Valuation

BRNS has a market cap or net worth of $29.00 million. The enterprise value is -$33.59 million.

Market Cap	29.00M
Enterprise Value	-33.59M

Important Dates

The last earnings date was Friday, November 7, 2025, before market open.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

BRNS has 40.83 million shares outstanding. The number of shares has increased by 3.60% in one year.

Current Share Class	n/a
Shares Outstanding	40.83M
Shares Change (YoY)	+3.60%
Shares Change (QoQ)	+0.79%
Owned by Insiders (%)	11.74%
Owned by Institutions (%)	24.10%
Float	35.89M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.34
P/TBV Ratio	0.42
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.04, with a Debt / Equity ratio of 0.14.

Current Ratio	8.04
Quick Ratio	7.33
Debt / Equity	0.14
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,097.24

Financial Efficiency

Return on equity (ROE) is -62.25% and return on invested capital (ROIC) is -25.56%.

Return on Equity (ROE)	-62.25%
Return on Assets (ROA)	-23.02%
Return on Invested Capital (ROIC)	-25.56%
Return on Capital Employed (ROCE)	-55.75%
Revenue Per Employee	n/a
Profits Per Employee	-$722,648
Employee Count	105
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-115,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.15% in the last 52 weeks. The beta is -0.69, so BRNS's price volatility has been lower than the market average.

Beta (5Y)	-0.69
52-Week Price Change	-15.15%
50-Day Moving Average	1.20
200-Day Moving Average	1.08
Relative Strength Index (RSI)	25.29
Average Volume (20 Days)	137,178

Short Selling Information

Short Interest	40,612
Short Previous Month	34,250
Short % of Shares Out	0.15%
Short % of Float	n/a
Short Ratio (days to cover)	0.30

Income Statement

Revenue	n/a
Gross Profit	10.52M
Operating Income	-54.86M
Pretax Income	-76.06M
Net Income	-75.88M
EBITDA	-51.70M
EBIT	-54.86M
Earnings Per Share (EPS)	-$1.88

Balance Sheet

The company has $74.27 million in cash and $11.57 million in debt, giving a net cash position of $62.70 million or $1.54 per share.

Cash & Cash Equivalents	74.27M
Total Debt	11.57M
Net Cash	62.70M
Net Cash Per Share	$1.54
Equity (Book Value)	84.56M
Book Value Per Share	2.07
Working Capital	75.98M

Cash Flow

In the last 12 months, operating cash flow was -$30.65 million and capital expenditures -$315,000, giving a free cash flow of -$30.97 million.

Operating Cash Flow	-30.65M
Capital Expenditures	-315,000
Free Cash Flow	-30.97M
FCF Per Share	-$0.76

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

BRNS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.60%
Shareholder Yield	-3.60%
Earnings Yield	-260.60%
FCF Yield	-106.35%

Analyst Forecast

The average price target for BRNS is $4.00, which is 463.14% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.00
Price Target Difference	463.14%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BRNS has an Altman Z-Score of -3.52 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.52
Piotroski F-Score	1